1-Bromo-1H-benzo[d]imidazole | 348619-95-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-Bromo-1H-benzo[d]imidazole
• 英文别名: 1-bromobenzimidazole
• CAS: 348619-95-4
• 化学式: C₇H₅BrN₂
• 分子量: 197.03
• InChiKey: FWZFVOARLMRVSR-UHFFFAOYSA-N

物化性质

• 沸点：
  303.6±25.0 °C(Predicted)
• 密度：
  1.69±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES COMME INHIBITEURS DE LA PROTÉINE TYROSINE KINASE
  申请人：ASTEX THERAPEUTICS LTD

  公开号：WO2009047506A1

  公开（公告）日：2009-04-16

  The invention relates to new bicyclic heterocyclic derivative compounds of formula (I): wherein R1, A, X1, X2, X3, X4, X5 and R2 are as defined herein, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

  这项发明涉及公式（I）的新的双环杂环衍生物化合物，其中R1、A、X1、X2、X3、X4、X5和R2如本文所定义，以及包含该化合物的药物组合物，以及该化合物在治疗疾病（例如癌症）中的用途。
• BENZIMIDAZOLES AS CNS ACTIVE AGENTS
  申请人：HOFFMANN-LA ROCHE INC.

  公开号：US20150203472A1

  公开（公告）日：2015-07-23

  The present invention relates to compounds of general formula wherein R 1 hydrogen, lower alkyl, halogen or lower alkyl substituted by halogen; R 2 is hydrogen or halogen; X 1 is N or CH; X 2 is N or CH; with the proviso that only one of X 1 or X 2 is N; X 3 is C(R) or N; and R is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen, lower alkoxy or SO 2 -lower alkyl; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.

  本发明涉及一般式化合物 其中 R 1 为氢、较低的烷基、卤素或被卤素取代的较低烷基; R 2 为氢或卤素; X 1 为N或CH; X 2 为N或CH; 但X 1 或X 2 仅有一个为N; X 3 为C(R)或N; 而R为氢、较低的烷基、卤素、被卤素取代的较低烷基、较低的烷氧基或SO 2 -较低烷基; 或者为药学上可接受的酸盐，或者为外消旋混合物或其相应的对映体和/或光学异构体。 这些化合物可用于治疗精神分裂症、强迫性人格障碍、重度抑郁症、双相情感障碍、焦虑障碍、正常衰老、癫痫、视网膜退化、创伤性脑损伤、脊髓损伤、创伤后应激障碍、恐慌障碍、帕金森病、痴呆症、阿尔茨海默病、轻度认知障碍、化疗引起的认知功能障碍、唐氏综合征、自闭症谱系障碍、听力丧失、耳鸣、脊髓小脑共济失调、肌萎缩侧索硬化、多发性硬化症、亨廷顿病、中风、放射治疗、慢性压力、滥用神经活性药物，如酒精、阿片类药物、甲基苯丙胺、芬太尼和可卡因。
• [EN] BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES UTILISÉS COMME INHIBITEURS DE LA PROTÉINE TYROSINE KINASE
  申请人：ASTEX THERAPEUTICS LTD

  公开号：WO2009047522A1

  公开（公告）日：2009-04-16

  The invention relates to new bicyclic heterocyclic derivative compounds of formula (I): wherein R1, q, A, B, X1, X2, X3, X4, X5 and R2 are as defined herein, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

  该发明涉及公式（I）的新的双环杂环衍生物化合物，其中R1、q、A、B、X1、X2、X3、X4、X5和R2如本文所定义，以及包含该化合物的药物组合物，以及该化合物在治疗疾病（例如癌症）中的用途。
• [EN] CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES<br/>[FR] ARYLALKYLAMINES MODULANT UN RECEPTEUR CALCIQUE
  申请人：AMGEN INC

  公开号：WO2003099776A1

  公开（公告）日：2003-12-04

  The compounds of the invention are represented by the following general structure (I) or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  该发明的化合物由以下一般结构（I）或其药用可接受盐所代表，以及含有它们的组合物，其中变量在此处定义，并且它们的用途是减少或抑制PTH分泌，包括减少或抑制PTH分泌的方法以及用于治疗或预防与骨骼疾病相关的疾病的方法，例如骨质疏松症，或与PTH过度分泌相关的疾病，例如甲状旁腺功能亢进症。该主题发明还涉及制备此类化合物的过程，以及在此类过程中有用的中间体。
• INHIBITORS OF ANTIGEN RECEPTOR-INDUCED NF-kappa B ACTIVATION
  申请人：REED John C.

  公开号：US20090247520A1

  公开（公告）日：2009-10-01

  A method to identify selective inhibitors of antigen receptor-mediated NF-κB activation is provided, as well as compositions having one or more of those inhibitors and methods of using those inhibitors.

  提供了一种识别抗原受体介导的NF-κB激活的选择性抑制剂的方法，以及具有一个或多个这些抑制剂的组合物和使用这些抑制剂的方法。